FDA Drug Info Rounds Video

Why It Matters

By providing authoritative, easily accessible guidance, the series helps clinicians meet regulatory requirements, improve patient safety, and accelerate access to needed therapies. This proactive communication strengthens the FDA’s partnership with the health‑care community.

Key Takeaways

• FDA offers free video series for healthcare professionals
• Topics include safety reporting, expanded access, and medication guides
• Series enhances compliance with FDA regulations and patient safety
• Content updated regularly, covering emerging drug policy issues
• Accessible via FDA website and podcast RSS feed

Pulse Analysis

The FDA’s Center for Drug Evaluation and Research (CDER) has expanded its outreach to clinicians through the Drug Info Rounds video series, a free, on‑demand library that translates complex regulatory guidance into concise, visual lessons. By leveraging short‑form video and podcast formats, the agency meets busy health‑care professionals where they are—online, on mobile devices, and during brief workflow gaps. This modern communication channel reinforces the FDA’s commitment to transparency and supports the broader public‑health mission of delivering reliable drug safety information and fosters interdisciplinary collaboration across sectors.

Topics span the full spectrum of drug stewardship, from filing MedWatch safety reports and navigating Medication Guide distribution requirements to completing Form FDA 3926 for expanded‑access applications. Episodes also demystify foreign manufacturing oversight, risk evaluation and mitigation strategies (REMS), and emerging issues such as antibiotic resistance and breakthrough‑therapy designations. By breaking down regulatory forms, databases like the Electronic Orange Book, and compliance timelines, the series equips pharmacists, physicians, and allied staff with actionable knowledge that can be applied at the point of care and supports evidence‑based prescribing decisions.

For pharmaceutical companies and health systems, the series offers a low‑cost training resource that can reduce reporting errors, accelerate patient access to investigational therapies, and improve adherence to FDA mandates. As the regulatory landscape evolves—particularly with increasing reliance on digital submissions and real‑world evidence—ongoing educational content will be essential to maintain alignment between industry practices and agency expectations. Continued investment in accessible, expert‑led videos positions the FDA as a proactive partner in safeguarding the drug supply chain, strengthening regulatory compliance culture, and enhancing patient outcomes.